Phase II Study on Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (FOLFOXIRI/ Bevacizumab).

Trial Profile

Phase II Study on Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (FOLFOXIRI/ Bevacizumab).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2013

At a glance

  • Drugs Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Cancer metastases; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms APRIORI
  • Most Recent Events

    • 24 Mar 2012 Actual initiation date changed from 1 June 2009 to 4 May 2009 as reported by European Clinical Trials Database.
    • 14 Jul 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 26 May 2011 Planned end date changed from 1 Feb 2013 to 1 Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top